Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tafolecimab in Chinese Patients With Homozygous Familial Hypercholesterolemia
NCT04948008Phase 3Unknown
- Sponsor
- Shenzhen People's Hospital
- Start
- Nov 2019
- Primary completion
- Jul 2020
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of tafolecimab in homozygous familial hypercholesterolemia (HoFH), sponsored by Shenzhen People's Hospital. Status: unknown.
02
Drugs
tafolecimab
03
Conditions
homozygous familial hypercholesterolemia (HoFH)
Beyond the preview
Go deeper on NCT04948008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04948008.